1.90
3.26%
0.06
Vyne Therapeutics Inc Aktie (VYNE) Neueste Nachrichten
HC Wainwright Reiterates Buy Rating for VYNE Therapeutics (NASDAQ:VYNE) - Defense World
VYNE reports positive early trial results for inflammation drug - Investing.com
VYNE reports positive early trial results for inflammation drug - Investing.com India
VYNE Therapeutics announces results from Phase 1a SAD trial for VYN202 - TipRanks
VYNE reports positive early trial results for inflammation drug By Investing.com - Investing.com UK
VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor - StockTitan
VYNE Therapeutics to Participate in September Investor Conferences - StockTitan
VYNE Therapeutics sees cash runway through end of 2025 - TipRanks
VYNE Therapeutics (NASDAQ:VYNE) Stock Rating Reaffirmed by HC Wainwright - Defense World
VYNE Therapeutics Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Simply Wall St
VYNE Therapeutics reports Q2 EPS (22c) vs. ($3.09) last year - TipRanks
VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
VYNE Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update - StockTitan
VYNE Stock Earnings: VYNE Therapeutics Misses EPS, Beats Revenue for Q2 2024 - InvestorPlace
Virtu Financial LLC Takes Position in VYNE Therapeutics Inc. (NASDAQ:VYNE) - Defense World
VYNE Therapeutics (NASDAQ:VYNE) Shares Down 0.5% - Defense World
VYNE Therapeutics secures UK patent for inflammation drug - Investing.com
Latest Patent Grant Is Driving VYNE Therapeutics Stock Higher Today - News IMC
VYNE Therapeutics Announces Granting of Composition of Matter Patent for VYN202, a Novel BD2-Selective BET Inhibitor - StockTitan
One VYNE Therapeutics Insider Raised Stake By 55% In Previous Year - Yahoo Finance
VYNE Therapeutics Appoints Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development - citybiz
VYNE Therapeutics Announces Appointment of Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development - StockTitan
How Much Upside is Left in VYNE Therapeutics Inc. (VYNE)? Wall Street Analysts Think 626.2% - Yahoo News Malaysia
VYNE Therapeutics Insiders Are Down US$27k But Regain Some Losses - Simply Wall St
VYNE's Iain Stuart, PhD, Talks Promise of VYN202 and BET Inhibition in Inflammatory and Psoriatic Disease - Dermatology Times
VYNE Therapeutics Inc. (NASDAQ:VYNE) Short Interest Up 22.2% in June - Defense World
Why VYNE Therapeutics Shares Are Trading Higher By 82%; Here Are 20 Stocks Moving Premarket - Quantisnow
VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum - StockTitan
VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum - GlobeNewswire Inc.
VYNE Therapeutics Inc. (VYNE) Reports Q4 Loss, Misses Revenue Estimates - Yahoo News UK
Eventide Asset Management LLC Takes $3.25 Million Position in VYNE Therapeutics Inc. (NASDAQ:VYNE) - Defense World
H.C. Wainwright eyes VYNE stock as Phase 1a trial commences - Investing.com India
H.C. Wainwright eyes VYNE stock as Phase 1a trial commences By Investing.com - Investing.com Canada
H.C. Wainwright eyes VYNE stock as Phase 1a trial commences By Investing.com - Investing.com Australia
H.C. Wainwright eyes VYNE stock as Phase 1a trial commences By Investing.com - Investing.com
VYNE Therapeutics (NASDAQ:VYNE) Rating Reiterated by HC Wainwright - Defense World
Analyst Scoreboard: 4 Ratings For VYNE TherapeuticsVYNE Therapeutics (NASDAQ:VYNE) - Benzinga
Fostering Mentorship and Support in Early-Stage Physician Assistants - Dermatology Times
VYNEVYNE Therapeutics Inc. Latest Stock News & Market Updates - StockTitan
VYNE Therapeutics Initiates Phase 2b Trial of BET Inhibitor VYN201 for Vitiligo - Dermatology Times
VYNE Therapeutics (NASDAQ:VYNE) Given Buy Rating at HC Wainwright - Defense World
PODCAST: From Infection to InnovationThe Turn Therapeutics Story - Dermatology Times
All You Need to Know About VYNE Therapeutics Inc. (VYNE) Rating Upgrade to Buy - Yahoo Movies UK
Short Interest in Volcon, Inc. (NASDAQ:VLCN) Grows By 46.0% - Defense World
Can VYNE Therapeutics Inc. (VYNE) Climb 415.04% to Reach the Level Wall Street Analysts Expect? - Yahoo Singapore News
Verrica Pharmaceuticals First Quarter 2024 Earnings: Beats Expectations - Simply Wall St
VYNE Therapeutics Inc. (NASDAQ:VYNE) Short Interest Update - Defense World
VYNE Therapeutics Inc. (VYNE) Reports Q1 Loss, Misses Revenue Estimates - Zacks Investment Research
VYNE Therapeutics'(NASDAQ:VYNE) Share Price Is Down 11% Over The Past Year. - Yahoo Movies UK
VYNE Therapeutics Inc. (VYNE) Reports Q1 Loss, Misses Revenue Estimates - Zacks Investment Research
VYNE Therapeutics Provides Updates on VYN201 for Nonsegmental Vitiligo and VYN202 for Inflammatory Diseases - Dermatology Times
Verve Therapeutics (VERV) Reports Q1 Loss, Tops Revenue Estimates - Zacks Investment Research
Verve Therapeutics (VERV) Reports Q1 Loss, Tops Revenue Estimates - Zacks Investment Research
Comparing Madrigal Pharmaceuticals (NASDAQ:MDGL) and VYNE Therapeutics (NASDAQ:VYNE) - Defense World
VYNE Therapeutics receives FDA approval for trial of VYN202 - Clinical Trials Arena
VYNE Therapeutics gets FDA nod for new drug trial - Investing.com
VYNE Therapeutics gets FDA nod for new drug trial - Investing.com India
Here's Why We're Watching VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Situation - Simply Wall St
VYNE Therapeutics (NASDAQ:VYNE) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):